Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD
Mital Jhaveri, Clinical Anticoagulation, Heart Failure Pharmacist at NYC HHC Queens Hospital Center, shared on LinkedIn about a recent article by Sunil V. Badve, published in JAMA, adding:
”New in JAMA: The TRACK Trial examined the impact of low-dose rivaroxaban (2.5 mg BID) on major adverse cardiovascular events in patients with advanced chronic kidney disease (CKD) (Stage 4–5) at high cardiovascular risk.
The findings indicate no benefit and increased harm.
- Primary composite cardiovascular outcome: 22.6% vs. 20.7% (HR 1.09; non-significant)
- Major bleeding: significantly higher in the rivaroxaban arm (8.8%)
- Trial halted early for futility
This study serves as a critical reminder that benefits established in the COMPASS and VOYAGER PAD trials do not apply to advanced CKD, a population with altered hemostatic and pharmacokinetic profiles.
As noted in the accompanying editorial, the TRACK trial should prompt a strategic pivot rather than an abandonment of the inquiry.
Bottom line: Low-dose rivaroxaban should not be used for primary cardiovascular protection in advanced CKD.”
Title: Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease. The TRACK Randomized Clinical Trial
Authors: Sunil V. Badve, Vlado Perkovic, Vivekanand Jha, Raja Ramachandran, Lily Mushahar, Jan Menne, An S. De Vriese, Patrick Rossignol, Adrien Flahault, Maha Al Ammari, Habib Skhiri, Michael Walsh, David Collister, Adrian Liew, Laurent Billot, Severine Bompoint, Anthony Devaux, Min Jun, Enmoore Lin, Aline Ramos da Cruz, Jeffrey T. Ha, John W. Eikelboom, Ahmed Shaman, Meg J. Jardine, Shilpanjali Jesudason, Muh Geot Wong, Craig S. Anderson, Amit X. Garg, Hiddo J. L. Heerspink, Helen Monaghan, Anushka Patel, Patrick B. Mark, David C. Wheeler, Jicheng Lv, Li Zuo, Helen Pilmore, Martin Gallagher

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 1, 2026, 11:07Yashaswi Dhiman: Advancing Hemovigilance Through Award-Winning Science
-
Aug 1, 2026, 08:24Kayla Garrett: Transforming Expectations in Haemophilia A Care
-
Aug 1, 2026, 07:51Toyosi Onwuemene: Are We Measuring the Outcomes That Matter Most to Patients With TTP?
-
Aug 1, 2026, 07:51Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?
-
Aug 1, 2026, 07:38Danny Hsu: Recognizing Excellence in Scientific Leadership at ISTH 2026
-
Aug 1, 2026, 07:24Ulrich Sachs: A New Strategy to Prevent Platelet Transfusion Refractoriness
-
Aug 1, 2026, 07:12Gijs Aertssen: New Evidence on Joint Prosthesis Survival in Inherited Bleeding Disorders
-
Aug 1, 2026, 06:58Nora Abazi Emini: New Insights into Factor XIII in Atypical Haemolytic Uraemic Syndrome
-
Aug 1, 2026, 06:30Understanding Natural Anticoagulant Deficiencies – JTH